Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 7Phase 3 1

Status

Active not recruiting 4Completed 2Withdrawn 1

Sponsor Class

OTHER 21INDUSTRY 7NIH 1NETWORK 1

Study Type

Interventional 7

Sponsor

Cancer Type

Thoracic 3Gynecologic 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Melanoma 1Lung Neoplasms 1Lung Diseases 1Hereditary Sensory and Autonomic Neuropathies 1Carcinoma, Bronchogenic 1Bronchial Neoplasms 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × ceralasertib × Clear all
NCT03330847 2026-03-10

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

AstraZeneca

Phase 2 Active not recruiting
273 enrolled 22 charts
Breast

Triple Negative Breast Neoplasms

NCT05941897 2026-03-05

LOTOS

AstraZeneca

Phase 2 Active not recruiting
39 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT03334617 2025-10-27

HUDSON

AstraZeneca

Phase 2 Active not recruiting
528 enrolled 16 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04564027 2025-08-29

A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

AstraZeneca

Phase 2 Completed
54 enrolled 16 charts

Hereditary Sensory and Autonomic Neuropathies

NCT05061134 2025-07-31

MONETTE

AstraZeneca

Phase 2 Active not recruiting
194 enrolled 21 charts
Dermatologic

Melanoma

NCT02937818 2024-06-07

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

AstraZeneca

Phase 2 Completed
72 enrolled 29 charts
Thoracic

Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma

NCT04239014 2021-03-10

DUETTE

AstraZeneca

Phase 2 Withdrawn
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡